 |
|
|
|
 For more information please contact:
Kevin McGrath
212.245.4577
Kevin@cameronassoc.com |
QuickLinks:
Press Releases »
Client Website »
Stock Quote »
Client Calendar »
|
|
DARA Biosciences, Inc. (Nasdaq: DARA)
DARA BioSciences, Inc. ("DARA") is a Raleigh, North Carolina based development-stage pharmaceutical company that acquires promising therapeutic small molecules and develops them through proof of concept in humans for subsequent sale or out-licensing to larger pharmaceutical companies. Presently DARA has two drug candidates with cleared IND's (Investigational New Drug) Applications from the US FDA. One of these drug candidates KRN5500 has successfully completed a Phase 2a clinical trial treating cancer patients for neuropathic pain. It has a portfolio of drug candidates for neuropathic pain, type 2 diabetes, and psoriasis. For more information please contact the Company at 919-872-5578 or visit our web site at http://www.darabio.com.
|
March 1, 2010:
DARA BioSciences Closes at Market Private Placement Transaction
- download word.doc (40 Kb) »
|
December 23, 2009:
DARA BioSciences Reports on SurgiVision's Filing of a Registration Statement With the Securities and Exchange Commission for an Initial Public Offering (IPO)
- download word.doc (40 Kb) »
|
November 23, 2009:
DARA BioSciences Presented Results of Its Phase 2 Study for KRN5500 at the "12th International Conference on the Mechanisms and Treatment of Neuropathic Pain"
- download word.doc (40 Kb) »
|
November 4, 2009:
DARA BioSciences Secures Additional Intellectual Property Relating to Spicamycin
- download word.doc (40 Kb) »
|
October 22, 2009:
DARA BioSciences Regains NASDAQ Compliance
- download word.doc (40 Kb) »
|
October 13, 2009:
DARA BioSciences Signs Definitive Agreement to Raise Approximately $750,000 in Registered Direct Offering
- download word.doc (40 Kb) »
|
October 12, 2009:
DARA BioSciences and America Stem Cell Broaden Collaboration
- download word.doc (40 Kb) »
|
September 18, 2009:
DARA BioSciences Signs Definitive Agreement to Raise $1.2155 Million in Registered Direct Offering
- download word.doc (40 Kb) »
|
September 17, 2009:
DARA BioSciences Announces Receipt of NASDAQ Letter Citing Non-Compliance with Minimum Bid Price Rules
- download word.doc (40 Kb) »
|
September 15, 2009:
DARA BioSciences Will Present Phase 2a Study Results for KRN5500 at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain Meeting
- download word.doc (40 Kb) »
|
September 11, 2009:
Dara Biosciences Signs Definitive Agreement To Raise $2.5 Million In Registered Direct Offering
- download word.doc (40 Kb) »
|
